Physician profile
Andrew Chida
NPI 1043839061
$457.71
in general payments reported to CMS, 2019-2025
13 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.66 · 2024: $212 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $90.41 | 2023-2025 | Airsupra, Fasenra |
| Pfizer INC. | $66.62 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.70 | 2024-2025 | |
| Novo Nordisk INC | $44.69 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $33.47 | 2024-2025 | Evenity, Prolia |
| Exact Sciences Corporation | $33.12 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $21.54 | 2024 | |
| Lilly USA, LLC | $21.08 | 2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.88 | 2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $17.44 | 2024 | |
| Merck Sharp & Dohme LLC | $16.63 | 2024 | Capvaxive, Gardasil 9, Vaxneuvance |
| Actelion Pharmaceuticals US, INC. | $16.59 | 2025 | Uptravi, Opsumit |
| Phathom Pharmaceuticals, INC. | $13.54 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Chida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.